肝門部膽管癌根治術區域淋巴結清掃范圍探討_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 湯朝暉 , 魏妙艷 , 唐陳偉 , 全志偉

上海交通大學醫學院附屬新華醫院普外科（上海 200092）;

Corresponding?author：

湯朝暉, Email: tangzhaohui@yahoo.com

Keywords：

DOI：

10.7507/1007-9424.201806056

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 湯朝暉, 魏妙艷, 唐陳偉, 全志偉. 肝門部膽管癌根治術區域淋巴結清掃范圍探討. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(7): 775-778. doi: 10.7507/1007-9424.201806056 Copy

1.	Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg, 1996, 224(4): 463-475.
2.	Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut, 2012, 61(12): 1657-1669.
3.	Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet, 2014, 383(9935): 2168-2179.
4.	Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017.
5.	Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v28-v37.
6.	陳孝平, 項帥. 精準醫學時代肝門部膽管癌的治療. 中華消化外科雜志, 2018, 17(1): 3-8.
7.	中華醫學會外科學分會膽道外科學組, 解放軍全軍肝膽外科專業委員會. 肝門部膽管癌診斷和治療指南(2013 版). 中華外科雜志, 2013, 51(10): 865-871.
8.	Guglielmi A, Ruzzenente A, Campagnaro T, et al. Prognostic significance of lymph node ratio after resection of peri-hilar cholangiocarcinoma. HPB (Oxford), 2011, 13(4): 240-245.
9.	Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg, 2010, 251(4): 675-681.
10.	Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg, 2013, 258(1): 129-140.
11.	Buettner S, Margonis GA, Kim Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford), 2016, 18(6): 510-517.
12.	Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience. J Hepatobiliary Pancreat Sci, 2010, 17(4): 449-454.
13.	Kambakamba P, Linecker M, Slankamenac K, et al. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review. Am J Surg, 2015, 210(4): 694-701.
14.	Giuliante F, Ardito F, Guglielmi A, et al. Association of lymph node status with survival in patients after liver resection for hilar cholangiocarcinoma in an Italian multicenter analysis. JAMA Surg, 2016, 151(10): 916-922.
15.	Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
16.	Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg, 2012, 147(1): 26-34.
17.	Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg, 2013, 257(4): 718-725.
18.	Shirai Y, Yoshida K, Tsukada K, et al. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg, 1992, 79(7): 659-662.
19.	Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci, 2015, 22(3): 181-196.
20.	中國抗癌協會. 肝門部膽管癌規范化診治專家共識(2015). 中華肝膽外科雜志, 2015, 21(8): 505-511.
21.	Greene FL, Page DL, FIeming ID, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. New York: Springer, 2002.
22.	Edge S, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York: Springer, 2010.
23.	國際肝膽胰學會中國分會, 中華醫學會外科學分會肝臟外科學組. 膽管癌診斷與治療-外科專家共識. 臨床肝膽病雜志, 2015, 31(1): 12-16.
24.	Mao K, Liu J, Sun J, et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol, 2016, 31(2): 417-426.
25.	Hakeem AR, Marangoni G, Chapman SJ, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? Eur J Gastroenterol Hepatol, 2014, 26(9): 1047-1054.
26.	Ruys AT, Kate FJ, Busch OR, et al. Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter? HPB (Oxford), 2011, 13(12): 881-886.
27.	Unno M, Okumoto T, Katayose Y, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg, 2007, 14(5): 434-440.
28.	周倩靜, 張桃, 吳文, 等. MRI及MRCP評估肝門部膽管癌可切除性應用價值研究. 中國實用外科雜志, 2011, 31(4): 316-318.
29.	楊暉, 關志偉, 富麗萍, 等. ¹⁸F-FDG PET/CT 在肝外膽管細胞癌術前診斷及分期中的價值. 中華核醫學與分子影像雜志, 2017, 37(2): 65-69.
30.	王越琦, 王吉文, 張德祥, 等. 氟代脫氧葡萄糖 PET/CT 在肝門部膽管癌術前評估中的價值. 中華肝膽外科雜志, 2015, 21(3): 173-176.
31.	谷鑫金, 王保富, 劉榮. ¹⁸F-FDG PET/CT 在肝門部膽管癌術前評估中的應用. 中華醫學雜志, 2012, 93(20): 1409-1412.

1. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg, 1996, 224(4): 463-475.
2. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut, 2012, 61(12): 1657-1669.
3. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet, 2014, 383(9935): 2168-2179.
4. Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017.
5. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v28-v37.
6. 陳孝平, 項帥. 精準醫學時代肝門部膽管癌的治療. 中華消化外科雜志, 2018, 17(1): 3-8.
7. 中華醫學會外科學分會膽道外科學組, 解放軍全軍肝膽外科專業委員會. 肝門部膽管癌診斷和治療指南(2013 版). 中華外科雜志, 2013, 51(10): 865-871.
8. Guglielmi A, Ruzzenente A, Campagnaro T, et al. Prognostic significance of lymph node ratio after resection of peri-hilar cholangiocarcinoma. HPB (Oxford), 2011, 13(4): 240-245.
9. Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg, 2010, 251(4): 675-681.
10. Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg, 2013, 258(1): 129-140.
11. Buettner S, Margonis GA, Kim Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB (Oxford), 2016, 18(6): 510-517.
12. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience. J Hepatobiliary Pancreat Sci, 2010, 17(4): 449-454.
13. Kambakamba P, Linecker M, Slankamenac K, et al. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review. Am J Surg, 2015, 210(4): 694-701.
14. Giuliante F, Ardito F, Guglielmi A, et al. Association of lymph node status with survival in patients after liver resection for hilar cholangiocarcinoma in an Italian multicenter analysis. JAMA Surg, 2016, 151(10): 916-922.
15. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
16. Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg, 2012, 147(1): 26-34.
17. Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg, 2013, 257(4): 718-725.
18. Shirai Y, Yoshida K, Tsukada K, et al. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg, 1992, 79(7): 659-662.
19. Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci, 2015, 22(3): 181-196.
20. 中國抗癌協會. 肝門部膽管癌規范化診治專家共識(2015). 中華肝膽外科雜志, 2015, 21(8): 505-511.
21. Greene FL, Page DL, FIeming ID, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. New York: Springer, 2002.
22. Edge S, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York: Springer, 2010.
23. 國際肝膽胰學會中國分會, 中華醫學會外科學分會肝臟外科學組. 膽管癌診斷與治療-外科專家共識. 臨床肝膽病雜志, 2015, 31(1): 12-16.
24. Mao K, Liu J, Sun J, et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol, 2016, 31(2): 417-426.
25. Hakeem AR, Marangoni G, Chapman SJ, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? Eur J Gastroenterol Hepatol, 2014, 26(9): 1047-1054.
26. Ruys AT, Kate FJ, Busch OR, et al. Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter? HPB (Oxford), 2011, 13(12): 881-886.
27. Unno M, Okumoto T, Katayose Y, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg, 2007, 14(5): 434-440.
28. 周倩靜, 張桃, 吳文, 等. MRI及MRCP評估肝門部膽管癌可切除性應用價值研究. 中國實用外科雜志, 2011, 31(4): 316-318.
29. 楊暉, 關志偉, 富麗萍, 等. ¹⁸F-FDG PET/CT 在肝外膽管細胞癌術前診斷及分期中的價值. 中華核醫學與分子影像雜志, 2017, 37(2): 65-69.
30. 王越琦, 王吉文, 張德祥, 等. 氟代脫氧葡萄糖 PET/CT 在肝門部膽管癌術前評估中的價值. 中華肝膽外科雜志, 2015, 21(3): 173-176.
31. 谷鑫金, 王保富, 劉榮. ¹⁸F-FDG PET/CT 在肝門部膽管癌術前評估中的應用. 中華醫學雜志, 2012, 93(20): 1409-1412.

Previous Article
肝門部膽管癌的治療現狀與展望
Next Article
肝門部膽管癌切除術中右肝動脈重建技巧

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

肝門部膽管癌根治術區域淋巴結清掃范圍探討

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content